---

Highlights of October 2018

1. Zydus to buy Heinz’s India business, including Complan, for US$ 633 Million.
2. Quest Diagnostics has agreed to sell off its India medical diagnostics business to Strand Life Sciences, based in Bangalore, citing a changing business model.
3. Ipca Labs arm Ipca Pharmaceuticals Inc, USA, acquires 80% stake in US-based Bayshore Pharma for US$ 10.28 Million.
4. Dr. Reddy’s Laboratories’ wholly owned U.S. subsidiary Promius Pharma has sold rights of Cloderm (clocortolone pivalate) cream and its authorised generic to EPI Health.
5. Sanofi pays Denali US$ 125 Million to buy into RIPK1 program.
6. Roche taps Halozyme’s drug delivery tech for up to US$ 520 Million.
7. Dicerna pens US$ 100 Million upfront RNAi research pact with Eli Lilly.
8. AbbVie has acquired Galapagos’ cystic fibrosis pipeline for US$ 45 Million upfront.
9. Alexion buys RNAi therapies in Dicerna deal.
10. Takeda buys stake in Enterome’s microbiome Crohn’s drug with US$ 50 Million upfront.
11. Amgen buys US$ 66 Million stake in pocket-sized DNA sequencer maker Oxford Nanopore.
12. Sarepta licenses Lysogene’s Sanfilippo gene therapy in deal worth up to US$ 142 Million.
13. Otsuka and Proteus sign 5-year, US$ 88 Million digital pill partnership.
14. Dragonfly Therapeutics in US$ 695 Million cancer R&D pact with Merck.
15. Roche bags anti-cancer bispecific from GO Therapeutics with US$ 9 Million upfront.
16. AstraZeneca strikes big, multipart immuno-oncology deal with Innate worth US$ 170 Million.

Updates at Aagami: 

1. Aagami CEO to participate in the upcoming Bio-Europe (Copenhagen, Denmark, November 5–7, 2018) with 25+ one-to-one meetings already scheduled.
2. Client adds South Korea to existing Assignment given to Aagami for Japan and India.